Lynda Szczech
Intercept Pharmaceuticals Inc. · Intercept Pharmaceuticals · Intercept Pharmaceuticals, Inc
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lynda Szczech as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:16 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06488911 · To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and BezafibrateIntercept Pharmaceuticals · terminated · Primary Biliary Cholangitis · study director
- Ph2/Ph3NCT06121375 · Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomyIntercept Pharmaceuticals · terminated · Biliary Atresia · study director
- Ph2NCT05321524 · Obeticholic Acid in Pediatric Subjects With Biliary AtresiaIntercept Pharmaceuticals · terminated · Biliary Atresia · study director
- N/ANCT05293938 · A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC PatientsIntercept Pharmaceuticals · withdrawn · Primary Biliary Cholangitis · study director
- N/ANCT05292872 · Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC PatientsIntercept Pharmaceuticals · completed · Primary Biliary Cholangitis · study director
- Ph2NCT05239468 · Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBCIntercept Pharmaceuticals · completed · Primary Biliary Cholangitis · study director
- Ph2NCT04594694 · Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBCIntercept Pharmaceuticals · terminated · Primary Biliary Cholangitis · study director
- Ph4NCT02133534 · The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney DiseaseDuke University · terminated · Chronic Kidney Disease, High Cholesterol · principal investigator
- Ph4NCT00528788 · How Vitamin D Analogues Affect Endothelial Cells in Patients on DialysisDuke University · completed · Hyperparathyroidism, Secondary, Kidney Failure, Chronic · principal investigator
- N/ANCT00526747 · Erythropoietin Resistance in Anemia of Chronic Kidney DiseaseDuke University · completed · Anemia, Kidney Failure, Erythropoietin · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Analysis of associations between anemia correction in CKD and mortality: CHOIRR01DK080094 · NIDDK · DUKE UNIVERSITY · fiscal years 2008 to 2009 · $166,556 awarded in 2009Same name and institution; not confirmed by an ID
- AN OBSERVATIONAL STUDY OF THE PHARMACOKINETICS OF EFAVIRENZ, NEVIRAPINE, AND LOPM01RR000030 · NCRR · DUKE UNIVERSITY · fiscal years 2005 · $14,029 awarded in 2005Same name and institution; not confirmed by an ID
- EPIDEMIOLOGY AND CLINICAL COURSE OF HIV NEPHROPATHYK23DK002724 · NIDDK · DUKE UNIVERSITY · fiscal years 2000 to 2004 · $102,843 awarded in 2004Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:16 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- Correction of anemia with epoetin alfa in chronic kidney disease.N Engl J Med · 20062,126 citationsRCR 57.7
- Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.N Engl J Med · 2019495 citationsRCR 21.8
- 488 citationsRCR 21.1
- Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.Kidney Int · 2008448 citationsRCR 12.9
- Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.Clin J Am Soc Nephrol · 2016232 citationsRCR 8.8
- 221 citationsRCR 8.6
- Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation.Circulation · 2002184 citationsRCR 4.4
- Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.Nephrol Dial Transplant · 2017170 citationsRCR 6.6
- Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial.J Am Soc Nephrol · 2005166 citationsRCR 5.2
- Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients.Kidney Int · 2007157 citationsRCR 5.2